CoChat

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases

Open access
Courtier, Frédéric, Carbuccia, Nadine, Garnier, Séverine, Guille, Arnaud, Adélaïde, José, Cervera, Nathalie, Gelsi-Boyer, Véronique, Mozziconacci, Marie-Joelle, Rey, Jérôme, Vey, Norbert, Chaffanet, Max, Birnbaum, Daniel, Murati, Anne · 2017 · Haematologica
Cited by 50

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Myeloproliferative neoplasms (MPNs) are chronic, clonal hematopoietic disorders that include polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF). A substantial proportion transforms into acute myeloid leukemia (AML) with a dismal prognosis. Mutually-exclusive hotspot driver mutations in JAK2, CALR, and MPL genes are present in 90% of PV, ET and PMF. The remaining 10% of cases are called triple negatives (TN). Mutations in other genes (e.g., ASXL1, DNMT3A, EZH2, IDH1/2, SH2B3, SRSF2, TET2) are also recurrent in MPNs. To better define the genetic events involved in MPN evolution and transformation, we studied 57 MPNs in chronic phase and 38 post-MPN AMLs from the IPC/CRCM Tumor Bank (authorization #AC-2007-33). Patients were appropriately informed and asked to consent in writing, in compliance with French and European regulations. MPN diagnosis was established according to the revised criteria of the World Health Organization. The 57 chronic cases were separated into two groups: 40 without acute evolution, arbitrarily called “steady” MPNs or sMPNs (median follow up was 17.9 years (11–28)); and 17 that transformed to AML, called tMPNs (median time between diagnosis of chronic and acute phases was 8.5 years (1– 29)). The latter group had 17 matched postMPN AML samples among the 38 cases of post-MPN AML. Genomic analysis was carried out for most patients in chronic phase during disease course, not at diagnosis. Median time between diagnosis and sample was 12.9 years (2–24 years) for sMPNs, and 5.7 years (0-25) for tMPNs (Online Supplementary Table S1). Post-MPN AML

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2016.152363

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 50

Metadata

Authors
Courtier, F., Carbuccia, N., Garnier, S., Guille, A., Adélaïde, J., Cervera, N., Gelsi-Boyer, V., Mozziconacci, M.-J., Rey, J., Vey, N., Chaffanet, M., Birnbaum, D., & Murati, A.
Venue
Haematologica
Published
2016-10-14
Volume
102
Issue
1
Pages
e11-e14
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2530439707
Cited by
50
References
3
FWCI
2.38
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. https://app.cochat.ai/papers/10.3324/haematol.2016.152363
The paper
Courtier, F., Carbuccia, N., Garnier, S., Guille, A., Adélaïde, J., Cervera, N., Gelsi-Boyer, V., Mozziconacci, M.-J., Rey, J., Vey, N., Chaffanet, M., Birnbaum, D., & Murati, A. (2017). Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica. https://doi.org/10.3324/haematol.2016.152363

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.